Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Dehydr
Post# of 420
(Total Views: 272)
Posted On: 10/26/2021 4:01:34 PM
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
- Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology
- It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls
- Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high brain tissue delivery
Lexaria Bioscience’s (NASDAQ: LEXX) just-concluded oral tetrahydrocannabinol (“THC”) absorption animal study, THC-A21-1, yielded promising results on the effectiveness of the company’s patented DehydraTECH(TM) drug delivery technology.
The study, performed by a leading, independent laboratory, involved 20 male Sprague Dawley rats split into two groups of ten each. It followed the administration of the THC with brain tissues collected at 8 and 24 hours (https://nnw.fm/bgdAH).
The study showed that DehydraTECH-THC delivered via oral ingestion required only 15 minutes to dispense THC levels proportional to those achieved at 45 minutes with concentration-matched controls. It also showed that DehydraTECH-THC delivered considerably more THC into the bloodstream compared to standard medium-chain triglyceride (“MCT” or “coconut oil”)- based control formulation, starting from the 2-minute mark onwards. It would then drop rapidly to the same level as the MCT control after 6 hours.
While making the announcement, Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”), noted, “THC users today include… medicinal and pharmaceutical users, all of whom need technology that doesn’t rely on harmful delivery methods such as smoking, but still provides rapid onset and high bioavailability which common oral formats do not offer.”
Mr. Bunka acknowledged that with DehydraTECH, Lexaria offers a solution that considers medical THC users’ needs. He noted that the findings from this study are proof of the technology’s rapid delivery, increased overall THC delivery, and high brain tissue delivery, all of which are consistent with the needs and wants of medical THC customers.
According to Harvard Medical School, medical cannabis use today is largely for pain control. Patients dealing with multiple sclerosis or nerve disorders have cited responding to cannabis treatment a lot better compared to opiates. This alternative has also proven to be more effective without the accompanying addictive or sedating effects linked to opiates. With DehydraTECH, Lexaria is proving that cannabis is not only integral to healthcare going forward but that it can also be administered effectively while still yielding better results for patients.
DehydraTECH processing consistently proves its ability to deliver drugs more effectively into the bloodstream and the brain tissue. The THC-A21-1 study is a testament to that and an indication of the tremendous potential that the technology has, not just with THC delivery but also with nicotine, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), phosphodiesterase inhibitors and anti-viral drugs, among others.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX3
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology
- It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls
- Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high brain tissue delivery
Lexaria Bioscience’s (NASDAQ: LEXX) just-concluded oral tetrahydrocannabinol (“THC”) absorption animal study, THC-A21-1, yielded promising results on the effectiveness of the company’s patented DehydraTECH(TM) drug delivery technology.
The study, performed by a leading, independent laboratory, involved 20 male Sprague Dawley rats split into two groups of ten each. It followed the administration of the THC with brain tissues collected at 8 and 24 hours (https://nnw.fm/bgdAH).
The study showed that DehydraTECH-THC delivered via oral ingestion required only 15 minutes to dispense THC levels proportional to those achieved at 45 minutes with concentration-matched controls. It also showed that DehydraTECH-THC delivered considerably more THC into the bloodstream compared to standard medium-chain triglyceride (“MCT” or “coconut oil”)- based control formulation, starting from the 2-minute mark onwards. It would then drop rapidly to the same level as the MCT control after 6 hours.
While making the announcement, Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”), noted, “THC users today include… medicinal and pharmaceutical users, all of whom need technology that doesn’t rely on harmful delivery methods such as smoking, but still provides rapid onset and high bioavailability which common oral formats do not offer.”
Mr. Bunka acknowledged that with DehydraTECH, Lexaria offers a solution that considers medical THC users’ needs. He noted that the findings from this study are proof of the technology’s rapid delivery, increased overall THC delivery, and high brain tissue delivery, all of which are consistent with the needs and wants of medical THC customers.
According to Harvard Medical School, medical cannabis use today is largely for pain control. Patients dealing with multiple sclerosis or nerve disorders have cited responding to cannabis treatment a lot better compared to opiates. This alternative has also proven to be more effective without the accompanying addictive or sedating effects linked to opiates. With DehydraTECH, Lexaria is proving that cannabis is not only integral to healthcare going forward but that it can also be administered effectively while still yielding better results for patients.
DehydraTECH processing consistently proves its ability to deliver drugs more effectively into the bloodstream and the brain tissue. The THC-A21-1 study is a testament to that and an indication of the tremendous potential that the technology has, not just with THC delivery but also with nicotine, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), phosphodiesterase inhibitors and anti-viral drugs, among others.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX3
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼